Archives
-
In Silico Peptide Screening to Inhibit TEM-1 β-Lactamase Act
2026-06-18
A new computational approach, MDockPeP2_VS, enables large-scale in silico screening of protein-binding peptides, overcoming longstanding challenges in peptide drug discovery. Applied to Escherichia coli TEM-1 β-lactamase, this method identified potent peptide inhibitors, offering new avenues for antibiotic resistance research.
-
Glycolytic Metabolites Restrict cGAS-Driven Inflammation in
2026-06-17
A recent study uncovers phosphoenolpyruvate’s (PEP) role as an endogenous inhibitor of the cGAS–STING pathway, restricting chronic inflammation and promoting healthy aging. These findings reveal a conserved metabolic adaptation with major implications for research on energy homeostasis, inflammation, and age-related disease intervention.
-
Bestatin Enables Chemical Dissection of Jasmonate Signaling
2026-06-17
This study demonstrates that bestatin, an aminopeptidase inhibitor, serves as an effective chemical genetic tool for dissecting jasmonate (JA) signaling in Arabidopsis. Through molecular and phenotypic characterization of bestatin-resistant mutants, previously unknown loci in JA-mediated plant defense and development were identified, advancing our understanding of plant hormonal signaling networks.
-
Scenario-Driven Solutions with CHI3L1-IN-5 (Compound Z17, C8
2026-06-16
This article provides an evidence-based, scenario-driven exploration of CHI3L1-IN-5 (Compound Z17, CAS No. 2249043-42-1, SKU C8756) for neuroinflammation and cell-based assays. Researchers and lab technicians will find practical guidance on optimizing experimental reproducibility and interpreting data when working with CHI3L1-mediated NF-κB pathway modulation. The content emphasizes product reliability, protocol insights, and direct links to validated resources.
-
MAPK10 Phosphorylation of KRT16 Suppresses NSCLC Metastasis
2026-06-16
This study reveals that MAPK10 limits non-small cell lung cancer (NSCLC) metastasis through phosphorylation-dependent ubiquitination and degradation of keratin 16 (KRT16). The findings highlight the MAPK10/KRT16/RNF213 axis as a clinically relevant pathway influencing cancer progression and prognosis.
-
Synergistic MOF Nanoparticles for Melanoma Photothermal-Immu
2026-06-15
Hao et al. present a modular, glutathione-responsive MOF nanoparticle system integrating indocyanine green and a PD-1 inhibitory peptide to achieve combined photothermal and immunotherapy for melanoma. This approach demonstrates enhanced tumor ablation and immune activation, offering a promising platform for overcoming limitations of single-modality cancer treatments.
-
JNJ-26481585 (Quisinostat): Precision HDAC Inhibition Workfl
2026-06-15
JNJ-26481585 (Quisinostat) stands out as a potent, second-generation HDAC inhibitor for apoptosis induction and tumor growth inhibition in resistant cancer models. This guide translates recent breakthroughs on TRIM21-ERK1/2 signaling into actionable lab protocols, empowering researchers to tackle drug resistance and dissect epigenetic modulation with confidence.
-
Cell lysis buffer for WB and IP: Precision in Protein Extrac
2026-06-14
Unlock robust, reproducible protein extraction with Cell lysis buffer for WB and IP, engineered for non-denaturing conditions and advanced protease/phosphatase inhibition. Discover how this optimized buffer streamlines workflows from tumor microenvironment research to reliable Western blot and immunoprecipitation results.
-
Cl-Amidine Trifluoroacetate Salt: PAD4 Inhibition in Transla
2026-06-13
This thought-leadership article explores how Cl-Amidine (trifluoroacetate salt) is reshaping PAD4-driven mechanistic studies and translational workflows in cancer, immune, and septic shock research. By integrating mechanistic insight, comparative landscape, and workflow strategies, it presents actionable guidance for researchers seeking to translate PAD4 inhibition into meaningful biological and therapeutic advances.
-
Murine RNase Inhibitor: Elevating RNA Integrity for Translat
2026-06-12
This thought-leadership article explores the mechanistic underpinnings and translational imperatives of RNA integrity preservation, spotlighting the Murine RNase Inhibitor as a pivotal tool for safeguarding RNA in high-stakes molecular workflows. By bridging discoveries in ribosome quality control and neurodevelopmental research, it provides strategic guidance to translational researchers on optimizing RNA workflows to unlock next-generation therapeutic and diagnostic potential.
-
Structure-Based Screening Reveals NSP15 Inhibitors in SARS-C
2026-06-12
This study identifies thymopentin and oleuropein as potent natural product inhibitors of SARS-CoV-2 NSP15 using structure-based virtual screening and molecular dynamics. These findings highlight NSP15 as a promising target for antiviral drug development and demonstrate the value of computational approaches in rapid therapeutic discovery.
-
Cytochalasin D (SKU B6645): Reliable Actin Polymerization In
2026-06-11
This article provides a scenario-driven, evidence-based exploration of Cytochalasin D (SKU B6645) as an actin polymerization inhibitor for advanced cell viability, proliferation, cytotoxicity, and drug delivery assays. Bench scientists will find authoritative guidance on experimental design, protocol optimization, and vendor selection—highlighting why this reagent from APExBIO offers reproducibility and validated performance.
-
Nanoparticle Uptake in Corneal Cells: Size and Surface Effec
2026-06-11
This study systematically evaluates how nanoparticle size and surface chemistry influence uptake mechanisms in human corneal epithelial cells, with a focus on optimizing ocular drug delivery. The findings provide mechanistic insight into dominant endocytic pathways and inform rational design of nanoparticle-based therapies for eye diseases.
-
Griseofulvin: Strategic Insights for Translational Antifunga
2026-06-10
This article explores how Griseofulvin, a microtubule associated inhibitor, enables new frontiers in antifungal drug research. By integrating mechanistic evidence, advanced assay validation, and practical guidance, we offer translational researchers a blueprint for leveraging Griseofulvin in rigorous, reproducible, and strategically differentiated workflows.
-
DMXAA (Vadimezan): Advanced Protocols for Tumor Immunity Res
2026-06-10
DMXAA (Vadimezan) is at the forefront of cancer biology research, serving as a potent apoptosis inducer and anti-angiogenic agent with unique utility in both in vitro and in vivo models. This article delivers a practical, evidence-backed guide for maximizing experimental success, highlighting new synergy with nuclear-targeted delivery platforms to amplify innate anti-tumor immunity.